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ABSTRACT
Statins can have beneﬁcial cholesterol-independent effects on vascular contractility, which may
involve increases in the bioavailability of NO (nitric oxide) as a result of phosphorylation of eNOS
(endothelial NO synthase). Although this has been attributed to phosphorylation of Akt (also
known as protein kinase B), studies in cultured cells have shown that statins can phosphorylate
AMPK (AMP-activated protein kinase); it is unknown whether this has functional effects in intact
arteries. Thus we investigated the acute effects of simvastatin on resistance arterial contractile
function, evaluating the involvement of NO, Akt and AMPK. Isolated rat mesenteric resistance
arteries were mounted on a wire myograph. The effects of incubation (1 and 2 h) with simvastatin
(0.1 or 1 μM) on contractile responses were examined in the presence and absence of L-NNA (N-
nitro-L-arginine; 10 μM) or mevalonate (1 mM). Effects on eNOS, phospho-eNOS (Ser1177), and
total and phospho-Akt and -AMPK protein expression were investigated using Western blotting.
The effect of AMPK inhibition (compound C, 10 μM) on eNOS phosphorylation and contractile
responses were also studied. Simvastatin (1 μM, 2 h) signiﬁcantly reduced constriction to U46619
and phenylephrine and enhanced dilations to ACh (acetylcholine) in depolarized, but not in
U46619-pre-constricted arteries. These effects were completely and partially prevented by L-
NNA and mevalonate respectively. Simvastatin increased eNOS and AMPKα phosphorylation, but
had no effect on Akt protein expression and phosphorylation after 2 h incubation. Compound C
prevented the effects of simvastatin on eNOS phosphorylation and contractility. Thus simvastain
can acutely modulate resistance arterial contractile function via mechanisms that involve the
AMPK/phospho-eNOS (Ser1177)/NO-dependent pathway.
INTRODUCTION
Statins are some of the most commonly prescribed
drugs in clinical practice. Statins are widely used
in the treatment of hypercholesterolaemia as they
reduce the biosynthesis of cholesterol by inhibiting
the enzyme HMG-CoA (3-hydroxy-3-methylglutaryl-
CoA) reductase and blocking the conversion of
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HMG-CoA into mevalonate. Numerous studies have
shown that statin treatment signiﬁcantly reduces
cardiovascular-related morbidity and mortality in
patients both with and without coronary artery disease
[1,2]; however, it is now apparent that their beneﬁcial
effects on the cardiovascular system extend beyond their
lipid-lowering actions. These additional effects have led
to the recent consideration of statins for the primary
prevention of cardiovascular disease in patients without
elevated cholesterol [3,4].
The majority of the cholesterol-independent or
pleiotropic effects are attributable to effects on
endothelial function and, speciﬁcally, increases in the
bioavailability of endothelium-derived NO [5–7]. NO is
essentialforthemaintenanceofcardiovascularhealthand
has numerous beneﬁcial effects including the regulation
of arterial tone and thus blood pressure. The pleiotropic
effects of statins are rapid with improved large arterial
endothelium-dependent dilation being noted within 3 h
of a single dose of statin in patients with normal serum
cholesterol levels [7]. Decreases in NO availability are
alsoobservedwithinhoursofsimvastatinwithdrawal[8].
The bioavailability of NO may be modulated in a variety
ofdifferentways,butpost-translationalphosphorylation
of eNOS (endothelial NO synthase) appears to be
particularly important for acute regulation of NOS
activity in endothelial cells [9]. The most widely studied
phosphorylation pathway involves the serine/threonine
Akt (also known as protein kinase B), which can
phosphorylate eNOS on Ser1177, resulting in activation
of the enzyme and increased production of NO [10,11].
Statin modulation of eNOS activity via this pathway has
beendemonstratedinculturedendothelialcells,although
this is not a uniform ﬁnding [12,13]. AMPK (AMP-
activated protein kinase) is another serine/threonine
kinase that has long been known to play a central role
in the regulation of energy homoeostasis [14]. It is now
evidentthatAMPKmaymodulatemultiplephysiological
andpathophysiologicalpathwaysincludingenhancement
of eNOS activity by phosphorylation [15–17]. Studies in
animal models have shown that acute infusion of AICAR
(5-amino-4-imidazolecarboxamide riboside; a selective
experimental AMPK activator) induces resistance arterial
dilation [18]. Given the beneﬁcial effects of AMPK
on both metabolism and endothelial function there
has been a recent surge of interest in identiﬁcation of
potentialclinicalactivatorsoftheenzyme.RapidAMPK-
dependent activation of eNOS has been demonstrated
in both cultured endothelial cells and in mouse aorta
following in vivo statin (atorvastatin and pravastatin)
treatment [19,20], but it is unknown whether this may
contribute to the acute effects of statins on arterial
reactivity.
Theaimofthepresentstudywasthustoinvestigatethe
acute effects of simvastatin, one of the most widely used
andcost-effectivestatinsprescribedinclinicalpractice,on
resistancearterialfunction,evaluatingtheinvolvement of
NO, Akt and AMPK.
MATERIALS AND METHODS
Animals
All studies were performed on tissues isolated from male
Wistar rats (200–250 g, n=57). Animals were housed
under a 12 h light/12 h dark cycle and had unlimited
access to food and water. Rats were killed by stunning
and cervical dislocation. The mesenteric vascular bed
was removed and placed in ice-cold PSS (physiological
salt solution) (119 mM NaCl, 4.7 mM KCl, 2.4 mM
MgSO4 ·7H2O, 25 mM NaHCO3, 1.18 mM KH2PO4,
0.07 mMEDTA,6.05 mMglucoseand1.6 mMcalciumat
pH 7.4). All studies were carried out in accordance with
theUnitedStatesNIHguidelines[GuidefortheCareand
Use of Laboratory Animals (1985), DHEW Publication
No. (NIH) 85-23: Ofﬁce of Science and Health Reports,
DRR/NIH, Bethesda, MD, U.S.A.], the University of
ManchesterAnimalExperimentationGuidelines,andthe
U.K. Animals (Scientiﬁc Procedures) Act 1986.
Drugs and solutions
Unless otherwise stated, all drugs were obtained
from Sigma, except U46619 which was obtained from
Calbiochem. A 10 mM stock solution of U46619 was
made by dissolving in a mixture of 100% ethanol
and 1 mg/kg Na2CO3 (1:2). 10 mM stock solution of
mevalonic acid lactone, simvastatin and compound C
were dissolved in DMSO (Merck). All other drugs were
dissolved in PSS.
Myography
Third-/fourth-order mesenteric arteries were dissected
out, cleared of fat and connective tissue, cut into small
segments (2–4 mm) and mounted in the chamber of a
wire myograph (Danish Myo Technology A/S) [21].
After mounting, tissues were equilibrated for 30 min
in PSS (gassed with 20% O2 and 5% CO2 at 37◦C)
and normalized as previously described [21]. Isometric
tension development was continuously recorded (Myo-
daq data acquisition system). Contractile viability was
assessedbytwoexposurestohighK+ solution(modiﬁed
PSS containing 120 mM KCl iso-osmotically substituted
for NaCl). Contraction induced by 120 mM KPSS
(potassium PSS; identical with PSS, except with sodium
replaced by potassium on an equimolar basis) in the con-
trol group was 3.23+ −0.17 mM/mm (n=31) compared
with 3.14+ −0.16 mM/mm (n=33) in the group that was
subsequently exposed to simvastatin (P>0.05). Func-
tional endothelial integrity was assessed by determining
relaxation to the endothelium-dependent dilator ACh
(acetylcholine; 10 μM) in thromboxane mimetic 9,11-
dideoxy-11α,9α-epoxy methanoprostaglandin (U46619,
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1 μM) pre-contracted rings; only the rings that relaxed
more than 80% to 10 μM ACh were included.
Cumulative concentration–response curves were con-
structed to U46619 (0.1 nM–1 μM) following incubation
with either 0.1 μMo r1 μM simvastatin for 1 or 2 h.
Theseconcentrationsaresimilartoplasmaconcentrations
in patients treated with therapeutic doses of statins
[22,23]. The inﬂuence of simvastatin on contractile
responses to the α-adrenergic agonist phenylephrine
(0.1 nM–1 μM) was also investigated. Time-control
experiments were performed in parallel. Cumulative
concentration–response curves to ACh (1 nM–10 μM)
and the endothelium-independent dilator SNP (sodium
nitroprusside; 1 nM–100 μM) were also constructed in
arteries pre-constricted with U46619. In the absence of
ACh or SNP, U46619 produced sustained contractions.
HMG-CoA reductase catalyses the production of
mevalonate from HMG-CoA. To determine whether
the acute effects of simvastatin were dependent on
the mevalonate pathway, arteries were incubated with
mevalonate (1 mM) for 2 h in both the absence
and presence of 1 μM simvastatin. Post-incubation,
concentration–response curves to U46619 and ACh were
constructed (see above).
To determine the role of NO in the acute effects
of simvastatin on contractile function, responses to
U46619 and to ACh were examined after incubation
for 2 h with either l-NNA (N-nitro-l-arginine; 10 μM)
alone or in combination with simvastatin (1 μM). To
further investigate the involvement of NO, the inﬂuence
of simvastatin (1 μM, 2 h) on responses to ACh was
investigated in arteries pre-constricted by 80 mM KPSS.
We have previously shown that relaxation to carbachol
is completely blocked by l-NNA in depolarized rat
mesenteric arteries [24].
The inﬂuence of simvastatin (1 μM, 2 h) on contractile
responses to U46619 was also examined in the
presence of the AMPK inhibitor compound C {6-[4-(2-
piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo-
[1,5-a]pyrimidine} (10 μM) [19].
Western blot analysis
Isolated resistance mesenteric arteries were incubated
in PSS either in the presence or absence of simvastatin
(1 μM) for 2 h. In some experiments, arteries were
also incubated with the AMPK inhibitor compound
C( 1 0 μM) [21] both in the presence and absence of
simvastatin(1 μM)for2 h.Followingincubation,arteries
were immediately frozen until required. Arteries were
then homogenized in lysis buffer containing [RIPA
lysis buffer (Upstate) containing protease inhibitor
cocktail (1:5000 dilution; Sigma), 100 mmol/l sodium
ﬂuoride), 10 mmol/l sodium pyrophosphate,100 mmol/l
sodium orthovanadate and 10 mmol/l PMSF]. Protein
extracts (75 μg) were separated by SDS/PAGE (7.5%
gel) and then transferred on to PVDF membranes
(Amersham) using a Mini Trans-Blot Cell system (Bio-
Rad) (overnight, 40◦C) containing transfer buffer (25
mmol/l Tris, 190 mmol/l glycine, 20% methanol and
0.05% SDS) as described previously [25].
After blockade of non-speciﬁc sites with 5% non-
fat dried milk, membranes were incubated overnight
at 4◦C with the primary antibody against mouse anti-
eNOS (1:1000 dilution; Transduction Laboratories),
rabbit anti-phospho-eNOS (Ser1177) (1:1000 dilution;
Cell Signaling), rabbit anti-Akt-1/-2/-3 (1:400 dilution;
SantaCruzBiotechnology),rabbitanti-phospho-Akt-1/-
2/-3 (Ser473) (1:400 dilution; Santa Cruz Biotechnology),
rabbitanti-phospho-Akt-1/-2/-3(Thr308)(1:500dilution;
Santa Cruz Biotechnology), rabbit anti-AMPKα (1:500
dilution; Santa Cruz Biotechnology) or rabbit anti-
phospho-AMPKα (Thr172) (1:1000 dilution; Cell Signal-
ing). After washing, membranes were incubated for 2 h
at room temperature with an anti-(mouse IgG) antibody
(1:1500 dilution; Bio-Rad) for eNOS and an anti-(rabbit
IgG) antibody for phospho-eNOS (1:1500 dilution),
Akt-1/-2/-3, phospho-Akt-1/-2/-3 (at Ser473 and Thr308),
AMPKα andphospho-AMPKα (Thr172)(1:5000dilution;
Jackson ImmunoResearch). Membranes were thor-
oughly washed, and immunocomplexes were detected
using an enhanced horseradish peroxidase/luminol
chemiluminescence system (ECLPlus; Amersham) and
autoradiography (Hyperﬁlm ECL; Amersham). The
same membrane was used to determine α-actin protein
expression as an internal control using a monoclonal
mouse anti-α-actin antibody (1:30000 dilution; Sigma).
Immunoblot signals were quantiﬁed using Scion
Image.Alldensitometricrawdatavalueswerenormalized
to α-actin expression in the same sample run on the
same gel/membrane. This permitted the ratio of the
amounts of each protein of interest, relative to α-actin,
to be calculated and directly compared under each
experimental condition.
Data analysis and statistical procedures
U46619 or phenylephrine-induced contractions were
normalized to the contraction of each tissue to KPSS
(120 mM). Dilatory responses to ACh or SNP were
normalized to the maintained U46619 or KCl-induced
contraction. The maximum effect (Emax)a n dt h e
logarithm of the concentration of agonist that produced
half of the Emax (log EC50) were calculated using non-
linear regression analysis (GraphPad Prism Software).
All values are expressed as means+ −S.E.M. for the
number of animals used in each experiment. Results
were analysed using a two-way ANOVA for comparison
between groups or an unpaired Student’s t test when
appropriate. When ANOVA showed a signiﬁcant
treatment effect, Bonferroni’s post-hoc test was used to
compare individual means. Differences were considered
statistically signiﬁcant at P<0.05.
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Figure 1 Effect of incubation with simvastatin (0.1 and 1 μM) for 1 (A and C) or 2 (B and D) h on contractile responses
of isolated rat mesenteric small arteries to U46619 and ACh
Contractile responses to U46619 are normalized to the contractile response of each artery to KPSS (120 mM). Relaxation responses to ACh are normalizedt ot h e
maximum contractile response of each artery to U46619. Values are means+ −S.E.M. (N =number of animals). ∗P <0.05 compared with control, using a two-way
ANOVA.
RESULTS
Effects of acute incubation with
simvastatin on contractile responses
of isolated rat mesenteric arteries
Incubation of arteries for 1 h with either 0.1 or 1 μM
simvastatin had no signiﬁcant effect on U46619-induced
contraction (n=5 and 6 respectively: Figure 1A).
Incubation of arteries for 2 h with 0.1 μM simvastatin
was similarly ineffective (Figure 1B). However, 2 h
incubation with 1 μM simvastatin signiﬁcantly reduced
U46619-inducedconstriction(Figure1B),butnotarterial
sensitivity (as evidenced by log EC50 values) to U46619
(Table 1). In line with the results obtained with U46619,
2 h incubation with 1 μM simvastatin also reduced
contractile responses to phenylephrine, but had no
effect on sensitivity [Emax, 96.9+ −7.10% contraction to
KPSS (n=4) for Control compared with 68.2+ −12.57%
contraction to KPSS for Simvastatin (n=4) (P<0.05,
using a Student’s t test); −6.28+0.06 for control
compared with −6.23+0.06 for Simvastatin; (P>0.05,
using a Student’s t test)].
Incubation with simvastatin (0.1 or 1 μM; 1 or 2 h)
had no signiﬁcant effect on dilations to ACh or SNP in
arteriespre-constrictedwithU46619(Figures1Cand1D,
and Table 2).
Table 1 Changes in the maximal response (Rmax)a n d
sensitivity (log EC50) to U46619 in mesenteric resistance
arteries incubated for 1 or 2 h with DMSO (control) and
simvastatin (0.1 or 1 μM)
∗P <0.05 compared with control (ANOVA)
Treatment Rmax (% to KPSS) log EC50
1h
Control 114+ −18.5 −6.61+ −0.06 (n=6)
Simvastatin 0.1 μM 104+ −9.00 −6.71+ −0.11 (n=5)
Simvastatin 1 μM 116+ −15.0 −6.65+ −0.09 (n=6)
2h
Control 106+ −4.24 −6.85+ −0.11 (n=13)
Simvastatin 0.1 μM 112+ −6.93 −6.80+ −0.15 (n=6)
Simvastatin 1 μM5 2 + −12.5∗ −6.70+ −0.04 (n=10)
Effects of mevalonate
Incubation with mevalonate (1 mM) alone had no effect
on contractions to U46619 (n=8) (Figure2A). However,
thereductionincontractiontoU46619observedafter2 h
incubationwithsimvastatin(1 μM)waspartiallyrestored
following concomitant incubation with mevalonate plus
simvastatin (n=8) (Figure 2A). Arterial sensitivity to
U46619 was unaffected (Table 3). Mevalonate had no
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Table 2 Changes in the maximal response (Rmax) and sensitivity (log EC50) to ACh and SNP in mesenteric resistance arteries
incubated for 1 or 2 h with DMSO (control) and simvastatin (0.1 or 1 μM)
ACh SNP
Treatment Rmax (%) log EC50 Rmax (%) log EC50
1h
Control 71+ −12.1 −6.51+ −0.18 (n=6) 79+ −6.56 −6.74+ −0.15 (n=6)
Simvastatin 0.1 μM7 1 + −12.4 −6.63+ −0.19 (n=5) 84+ −7.97 −6.38+ −0.50 (n=5)
Simvastatin 1 μM7 2 + −10.3 −6.65+ −0.16 (n=6) 89+ −1.37 −6.74+ −0.12 (n=6)
2h
Control 85+ −4.30 −6.53+ −0.10 (n=12) 83+ −4.32 −6.38+ −0.19 (n=13)
Simvastatin 0.1 μM9 2 + −3.07 −6.60+ −0.17 (n=5) 87+ −2.71 −6.37+ −0.12 (n=6)
Simvastatin 1 μM7 9 + −5.12 −6.69+ −0.12 (n=10) 83+ −3.96 −6.65+ −0.16 (n=10)
Figure 2 Effect of incubation with mevalonate (1 mM) on responses to (A) U46619 and (B) ACh (in tissues pre-constricted
with U46619) in both the presence and absence of simvastatin (1 μMf o r2h )
Contractile responses to U46619 are normalized to the contractile response of each artery to KPSS (120 mM). Relaxant responses to ACh are normalized tot h e
maximum contractile response of each artery to U46619. Values are means+ −S.E.M. (N =number of animals). ANOVA two-way; ∗P <0.05 compared with control;
+P <0.05 compared with mevalonate; and #P <0.05 compared with simvastatin, using a two-way ANOVA.
Table 3 Changes in the maximal response (Rmax)
and sensitivity (log EC50) to U46619 in mesenteric
resistance arteries incubated for 2 h with DMSO (control),
simvastatin 1 μM, L-NNA (10 μM) or mevalonate (10 mM)
in the absence or presence of simvastatin (1 μM)
∗P <0.05 compared with control; +P <0.05 compared with simvastatin
(ANOVA).
Treatment Rmax (% to KPSS) log EC50
Control 106+ −4.24 −6.85+ −0.11 (n=13)
Simvastatin 52+ −12.5∗ −6.70+ −0.04 (n=10)
Mevalonate 111+ −3.01 −6.86+ −0.13 (n=8)
Mevalonate/simvastatin 83+ −8.25∗+ −6.72+ −0.12 (n=8)
L-NNA 111+ −6.92 −6.98+ −0.16 (n=7)
L-NNA/simvastatin 103+ −10.3 −6.98+ −0.13 (n=8)
effect on responses to ACh either in the presence or
absence of simvastatin (Figure 2B).
Involvement of NO, Akt and AMPK
Incubation with l-NNA had no signiﬁcant effect on
contraction to U46619 (n=7) (Figure 3A). However,
2 h co-incubation of l-NNA with 1 μM simvastatin
completelyblockedtheeffectsofsimvastatinonU46619-
induced contraction (n=8; Figure 3A and Table 3).
Arterial sensitivity to U46619 did not change among
groups (Table 3). The dilatory response to ACh in both
thepresence(n=8)andabsence(n=7)ofsimvastatinwas
reduced by l-NNA, although this only reached a level
of signiﬁcance in the presence of the statin (Figure 3B).
Arterial sensitivity to ACh was unaffected (results not
shown).
To investigate further the effects of simvastatin
(1 μM for 2 h) on NO, concentration–response curves
to ACh were also constructed in depolarized tissues
(80 mM KPSS). ACh-induced relaxation was reduced
in depolarized arteries (n=6) when compared with
that seen in U46619 pre-constricted arteries (n=12;
Figure 3C). Simvastatin (1 μM, 2 h) signiﬁcantly
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Figure 3 Involvement of NO in acute functional effects of simvistatin in isolated rat mesenteric arteries
The effect of 2 h incubation with L-NNA (10 μM) on responses of isolated rat mesenteric small arteries to (A) U46619 and (B) Ach (in tissues pre-constricted with
U46619) in both the presence and absence of simvastatin (1 μM for 2 h). (C) Comparison of the effects of 2 h incubation with 1 μM simvastatin on responses to ACh
when pre-constricted with U46619 (10 μM) or KCl (80 mM). Values are means+ −S.E.M. (N =number of animals). ∗P <0.05 compared with Control; +P <0.05
compared with L-NNA; and #P <0.05 compared with arteries pre-constricted with U46619, using a two-way ANOVA.
enhanced dilations of depolarized vessels to ACh (n=6;
Figure 3C).
Western blotting experiments showed that incubation
with simvastatin (1 μM for 2 h) increased the phos-
phorylation of eNOS on Ser1177 (Figure 4A), but did
not modify eNOS protein expression [eNOS/α-actin
protein expression, 0.93+ −0.10 in control compared with
0.86+ −0.10 with Simvastatin (n=5); P>0.05, using a
Student’s t test]. Phosphorylation of Akt-1/-2/-3 on
Ser473 or on Thr308 was not signiﬁcantly modiﬁed by
simvastatin (Figures 4C and 4D). Similarly, Akt-1/-
2/-3 protein expression was unaffected [Akt/α-actin
protein expression, 0.73+ −0.09 in Control compared
with 0.86+ −0.10 with Simvastatin (n=8); P>0.05,
using a Student’s t test]. However, simvastatin sig-
niﬁcantly increased phosphorylation of AMPKα on
Thr172 (Figure 4B), without any changes in AMPKα
protein expression [AMPKα/α-actin protein expression,
0.65+ −0.12 in Control compared with 0.71+ −0.04 with
Simvastatin (n=5); P>0.05, using a Student’s t test].
There were no changes in α-actin protein expression
between groups (results not shown).
Co-incubation of arteries with the AMPK inhibitor
compound C (10 μM) with simvastatin (1 μM, 2 h)
completely blocked the enhanced eNOS phosphoryla-
tion at Ser1177 seen with simvastatin alone (Figure 5A).
Similar effects were seen with the vascular reactivity
experiments; in the presence of the AMPK inhibitor
compound C (10 μM) and simvastatin (1 μM), U46619-
induced contractions were similar to those seen with
compound C alone (Figure 5B). Compound C alone
did have some effect on contractility to U46619 (Emax,
117+8.05% of contraction to KPSS for control and
82+ −12.2% of contraction to KPSS for compound C),
but simvastatin had no additional effect in the presence
of compound C (Emax,7 1+ −8.16% contraction to KPSS).
DISCUSSION
In the present study, we have clearly demonstrated
that short-term incubation with simvastatin can directly
modulate the contractility of isolated rat mesenteric
small arteries via a NO-dependent mechanism that is
associated with phosphorylation of AMPK and not
Akt 2 h after incubation. Simvastatin had no further
effect on contractility when AMPK was inhibited
with compound C. Although the emphasis of most
previous studies has been improvement of endothelial
function, in the present study endothelial function
was not compromised. Here the predominant effect of
simvastatinwasaNO-dependentreductionincontractile
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Figure 4 Effects of 2 h incubation of rat mesenteric arteries with 1 μM simvastatin (SIMV) on phosphorylation of (A) eNOS
(Ser1177) (B), AMPKα (Thr172) (C), Akt-1/-2/-3 (Ser473) and (D) Akt-1/-2/-3 (Thr308)
Upper panel: representative blot for phospho-eNOS (Ser1177) and eNOS (A), phospho-AMPKα (Thr172) and AMPKα (B), phospho-Akt-1/-2/-3 (Ser473) (C) or
phospho-Akt-1/-2/-3 (Thr308) (D) and Akt-1/-2/-3 protein expression in mesenteric resistance arteries incubated with simvastatin (SIMV) or vehicle (CT). Lower
panel: densitometric analysis of the ratio for phospho-eNOS (Ser1177) and eNOS (A), phospho-AMPKα (Thr172) and AMPKα (B), phospho-Akt-1/-2/-3 (Ser473) (C) and
phospho-Akt-1/-2/-3 (Thr308) (D) and Akt-1/-2/-3 protein expression. Phosphorylation of eNOS was signiﬁcantly increased in the presence of simvastatin. Simvastatin
had no effect on Akt phosphorylation at either site (Ser473 or Thr308), but signiﬁcantly increased phosphorylation of AMPKα (Thr172). Results are normalized to the
expression of α-actin. Values are means+ −S.E.M. (number of animals used is indicated on the bars). ∗P <0.05 compared with control using a Student’s t test. CT,
control.
Figure 5 Effects of the AMPK inhibitor compound C on responses to acute simvistatin (SIMV)
(A) The effect of the AMPK inhibitor compound C (10 μM) on enhanced phosphorylation of eNOS at Ser1177 induced by 2 h incubation with simvastatin 1 μM. Upper
panel: representative blot for phospho-eNOS (Ser1177) and eNOS protein expression in mesenteric resistance arteries incubated with vehicle (CT), simvastatin (SIMV),
compound C (CC) or compound C plus simvastatin (CC/SIMV). Bottom panel: densitometric analysis of the ratio for phospho-eNOS (Ser1177) and eNOS. Results are
normalized to the expression of α-actin. Values are means+ −S.E.M. (number of animals used is indicated on the bars). ∗P <0.05 compared with control using
a Student’s t test. (B) The effect of incubation with compound C (10 μM) on responses to U46619 in the presence and absence of simvastatin (1 μMf o r2h ) .
Contractile responses to U46619 are normalized to the contractile response of each artery to KPSS (120 mM). Values are means+ −S.E.M. (N =number of animals).
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responsiveness with enhancement of endothelium-
dependent dilation to ACh only evident in tissues
constricted by depolarization but not in those pre-
constricted with U466119. In depolarized tissues, in the
absenceofEDHF(endothelium-derivedhyperpolarizing
factor) action, maximal dilation to ACh was less than
that seen in U46619-pre-constricted tissues; as such there
is the capacity for enhancement of dilation. We have
previously shown that dilation of depolarized arteries
to ACh is entirely due to the release of NO [24]
supporting the notion that acute simvastatin enhanced
NO bioavailability.
Although it has been known for some time that statins
may directly modulate NO bioavailability and NO-
dependent vascular function, the mechanisms underlying
these effects appear multiple and may depend on
various factors, including the type, dose and duration
of statin exposure. These mechanisms may include
changes in the expression of eNOS mRNA and
protein [26–28], reductions in NO breakdown [29]
and, of particular importance in endothelial cells,
post-translational modiﬁcation of eNOS activity by
phosphorylation [9–13,30,31]. It is well established
that phosphorylation of eNOS at Ser1177 increases
its activity [9]. The most widely studied eNOS
phosphorylation pathway involves the serine/threonine
Akt and it is widely accepted that activation of Akt
by phosphorylation (Ser473) may also modulate vascular
contractility in an eNOS-dependent manner [10,32,33].
Previous studies have shown that treatment of
cultured endothelial cells with simvastatin causes rapid
phosphorylation of both Akt and eNOS increasing the
activity of the latter [11–13]. Such effects are thought
to contribute to the acute effects of cerivastatin on
endothelial function in isolated rat aorta [34]. However,
in the present study, no Akt phosphorylation at either
Ser473 or Thr308 (another possible phosphorylation site)
was observed after 2 h incubation. We report for the ﬁrst
time in intact arteries that the acute effects of simvastatin
onresistancearterialcontractilitymayinvolveanAMPK-
dependent pathway.
AMPK is an upstream kinase that plays a central
role in the regulation of energy homoeostasis [14].
Activation of AMPK is dependent on phosphorylation
of Thr172. Although it is well established that AMPK
activity is regulated by changes in the AMP/ATP ratio
[35], it is now clear that AMPK may also be activated
by AMP-independent pathways [36]. Activated AMPK
may have multiple actions including the activation of
eNOS via phosphorylation at Ser1177 [16,17]. This has
functional consequences as it has been shown that
the selective pharmacological AMPK activator AICAR
induces endothelium-dependent dilation of resistance
arteries [18]. Previous studies in cultured endothelial
cells have shown that atorvastatin can acutely increase
the phosphorylation of AMPK and subsequently eNOS
phosphorylation [19,37]. Chronic treatment of mice
with simvastatin has also been shown to increase aortic
AMPK phosphorylation, but it is unknown whether this
was associated with changes in eNOS phosphorylation
or alteration of vascular function [38]. In the present
study, we have shown that acute incubation of isolated
mesenteric arteries with simvastatin (2 h, 1 μM) reduced
contraction to both U46619 and phenylephrine via NO-
dependent mechanisms that were associated with AMPK
and eNOS phosphorylation. Furthermore, inhibition
of AMPK with compound C totally prevented the
statin-induced increase in eNOS phosphorylation (at
Ser1177). Although we acknowledge that compound C
did itself reduce contraction to U46619, in the presence
of compound C, simvastatin had no additional effect
on arterial contractility. Taken together our results
suggest that that phosphorylation of AMPK at Thr172
and subsequent phosphorylation of eNOS (at Ser1177)
is a fundamental mechanism underlying the pleiotropic
effects of the statin on resistance arterial contractility.
Whether further control may be afforded by AMPK
phosphorylation of eNOS at alternative sites is yet to
be determined [19,37].
The mechanism by which simvastatin enhances
AMPK phosphorylation is unclear. Simvastatin inhibits
HMG-CoA reductase which converts HMG-CoA into
mevalonicacid.Inthepresentstudy,thefunctionaleffects
of simvastatin were partially inhibited by mevalonate
suggesting that the effects we observed were partially
dependent on this pathway. Mevalonate is required not
only for the synthesis of steroids such as cholesterol,
but also for the production of a number of other
compounds including isoprenoids, ubiquinone and
dolichols. Isoprenoids are important regulators of a
variety of small molecules, including GTPases Rho, Rac1
and Ras [39], and have previously been implicated in
the effects of statins on eNOS expression and stability
(see [40]). Previous studies in cultured endothelial cells
havedemonstratedsimvastatinmayincreaseGTP-bound
Rac1 and increase AMPK phosphorylation [38]. Clearly
such a mechanism may contribute to the effects observed
in the present study, although further work is required
to clarify the involvement of mevalonate in the acute
effects of simvastatin on simvastatin-stimulated AMPK
and eNOS phosphorylation and upstream signalling
pathways involved.
In summary, we have shown that simvastatin acutely
directly modulates resistance arterial contractile function
in healthy animals via NO-dependent mechanisms that
are associated with an increased phosphorylation of
eNOS at Ser1177 via the AMPK pathway.
Perspectives
The role of AMPK in the maintenance and restoration
of metabolic homoeostasis has led to considerable
interest in it as a potential target for the treatment of
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metabolic disorders, including obesity, Type II diabetes
and the metabolic syndrome [41,42]. These disorders
are associated with endothelial dysfunction and indeed
cardiovascular disease is responsible for considerable
morbidity and mortality in these patients [43]. The
identiﬁcation of safe and effective compounds that
activate AMPK may represent an effective strategy to
improve both metabolic homoeostasis and endothelial
function in cardiometabolic disorders [14]. In support
of this notion the pharmacological activators of AMPK
A769662andAICARhavebeenshowntoelicitbeneﬁcial
effects on metabolism and endothelial function, but
problems of oral bioavailability and short half-life limit
their clinical use [18,44]. There is a continued search
for identiﬁcation of safe and effective modulators of
AMPK. In the present study, we show that, in addition
to those beneﬁts on endothelial function associated
with a reduction in cholesterol, simvastatin can acutely
modulate AMPK via phosphorylation of eNOS. Further
studies are clearly required to fully understand the
pleiotropic effects of statins on eNOS, to investigate the
relative importance of this mechanism with other statins
and the time- and dose-dependence of these effects.
Although the effects of statins on NO bioavailability are
multiple, the results of the present study do show that
simvastatin, which is a safe and cost-effective medication,
can modulate AMPK- and eNOS-dependent arterial
function even in the absence of endothelial dysfunction.
Such effects may represent a new strategy for use of
statins in both treatment and primary prevention of
cardiometabolic disorders.
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